BioTissue begins skin substitute study:
This article was originally published in Clinica
Executive Summary
German tissue engineering firm BioTissue Technologies has begun an international, multicentre study of its skin cell substitute, BioSeed-S, designed to generate data to support the coverage of the product by health insurance bodies. Professor Wolfgang Vanscheidt, director of the Wound Biology Clinic in Hochenschwand, Germany, and president of the German Wound Healing Association, is heading the study. BioSeed-S is already being marketed globally under an exclusive marketing deal between Freiburg-based BioTissue Technologies and Baxter International.